<div id="readability-page-1"><p>New World Advisors LLC grew its position in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 61.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,541 shares of the company's stock after purchasing an additional 1,347 shares during the quarter. New World Advisors LLC's holdings in Johnson &amp; Johnson were worth $541,000 as of its most recent filing with the SEC.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in  Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter.  Geode Capital Management LLC increased its holdings in shares of  Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the period.  Northern Trust Corp raised its position in  Johnson &amp; Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter.  Bank of New York Mellon Corp boosted its stake in  Johnson &amp; Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the period.  Finally, Legal &amp; General Group Plc grew its position in  Johnson &amp; Johnson by 6.2% during the 2nd quarter. Legal &amp; General Group Plc now owns 18,917,274 shares of the company's stock worth $2,889,614,000 after purchasing an additional 1,097,855 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors. </p><h2>Johnson &amp; Johnson Stock Performance</h2><p>NYSE:JNJ opened at $203.88 on Friday. The firm's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson &amp; Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $206.94. </p><ul><li>3 Smart Defensive Stocks for an Uneasy Market</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%.  Analysts expect that  Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio  is presently 50.19%. </p><h2>Insiders Place Their Bets</h2><ul><li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li></ul><p>In other Johnson &amp; Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson &amp; Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own  0.16% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities research analysts have recently commented on the stock. Citigroup upped their target price on shares of Johnson &amp; Johnson from $213.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 15th. The Goldman Sachs Group upped their price objective on Johnson &amp; Johnson from $186.00 to $212.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, October 9th. Scotiabank started coverage on Johnson &amp; Johnson in a research note on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 target price on the stock. Daiwa Capital Markets upgraded Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Finally, Wells Fargo &amp; Company  set a $212.00 price target on Johnson &amp; Johnson and gave the stock an &#34;overweight&#34; rating in a report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned  a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $201.05.</p><p><b>Check Out Our Latest Report on JNJ</b></p><h2>Johnson &amp; Johnson Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>What Makes a Stock a Good Dividend Stock?</li><li>MarketBeat Week in Review – 11/17 - 11/21</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li><li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li><li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>New World Advisors LLC increased its stake in Johnson & Johnson by 61.4% in Q2, owning 3,541 shares worth $541,000. Other institutional investors like Vanguard, Geode Capital, and Legal & General also adjusted their positions. Johnson & Johnson's stock opened at $203.88, with a market cap of $491.21 billion. The company announced a quarterly dividend of $1.30, payable on December 9th.</p>

New World Advisors LLC Increases Stock Position in Johnson & Johnson $JNJ